

# **Investigation on MMACHC-R161Q** pathological mutant from cbIC disease



Lisa Longo<sup>1,3</sup>, Loredana Randazzo<sup>1,</sup> Rita Carrotta<sup>1</sup>, Maria Assunta Costa<sup>1</sup>, Maria Rosalia Mangione<sup>1</sup>, Vincenzo Martorana<sup>1</sup>, Rosa Passantino<sup>1</sup>, Marco Tutone<sup>3</sup>, Maria Grazia Ortore<sup>2</sup>, Michela Bollati<sup>1</sup>, Matteo De Rosa<sup>1</sup>, Mario Milani<sup>1</sup>, Silvia Vilasi<sup>1</sup> 1. Institute of Biophysics, National Research Council, Italy; 2. Department of Life and Environmental Sciences, Marche Polytechnic University, Ancona, Italy; 3. Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy

# Background

The cblC disease is a rare disorder of vitamin B12 (cobalamin, Cbl) metabolism characterized by the abnormal accumulation of methylmalonic acid and homocysteine.

✤ The illness is caused by mutations in the gene coding for MMACHC [1], a 282 aa protein that transports and transforms the different forms of Cbl.

Although the **crystal structure of the wild-type (WT) protein** is available [2,3], many molecular features of MMACHC physiopathology remain to be understood and a systematic study on the effect of each specific mutation on the resulting protein is still lacking.

### **Cobalamin (Cbl) structure**

### Intracellular Cbl metabolism





R161Q is **able to bind Cbl**, as shown by the shift 530 nm  $\rightarrow$ 460 nm in Cbl absorbance maximum and related to base-on to base-off state transition due to the binding to MMACHC.

### **R161Q mutant**



However, the fluorescence quenching as a function of AdoCbl concentration revealed **less affinity** to the ligand for the mutant in comparison to WT.

### **Protein stability**



**Cobalamin** is a complex biomolecule consisting of a central cobalt atom surrounded by a corrin ring with various side chains.





**MMACHC** has the role to transport and process (by reaction 1 or 2) the different forms of Cbl.



# **Research goal**



Our aim is to characterize the impact of pathological mutations on MMACHC molecular properties, such as structure, stability, substrates/cofactors binding and catalytic activity, in order to provide a strong basis for further therapeutic development. Here we focus on MMACHC wild type and **p.R161Q**, a missense mutation that resides in the **GSH** binding pocket, associated with the late-onset disease.



1048

720

480

242

#### +AdoCbl Apo Wild type $Tm = (41.2 \pm 0.1)$ Tm = (48.4<u>+</u>0.1) p.R161Q $Tm = (37.7 \pm 0.1)$ $Tm = (40.8 \pm 0.1)$

Both WT and p.R161Q in their apo form are thermolabile proteins. Moreover, p.R161Q is less stable than WT and shows lower gain in stability due to the Cbl binding.

### **Dimer formation**



As shown by FPLC, <MW> values from Light Scattering and native gel electrophoresis, p.R161Q is ess form able to the dimers in presence of AdoCbl than WT.



# WT protein structure [4]

Small Angle X-ray Scattering (SAXS)



**Circular Dichroism (CD)** 



CD and SAXS experiments showed that recombinant WT MMACHC has a secondary structure in good agreement with the crystal structure of the protein [2,3] and it is **compact** in solution. Structural rearrangement occurring upon the protein-vitamin binding could be detected.

# References

[1] J. P. Lerner-Ellis et al., Nat Genet 38, 93-100 (2006). [2] M. Koutmos, C. et al., *J Biol Chem* 286, 29780-29787 (2011). [3] D. S. Froese et al., J Biol Chem 290, 29167-29177 (2012). [4] R. Passantino et al., BBA Proteins Proteom 1870(6), 140793 (2022). The comparison between the RMSD of the two simulations shows an **abrupt deviation** for the mutant at about 100 ns. This sudden increase, absent in WT protein, is associated to the extraction of the DMB tail of the Cbl out of its binding pocket, which is far from where the mutation actually occurs.

# **Functionality assay**



Addition of GSH to MMACHC WT with MeCbl resulted in the formation of OH<sub>2</sub>Cbl as revealed by the appearance of the characteristic peak at 355 nm in the CbI absorbance spectrum. No similar behavior could be observed with MeCbl incubated with the mutant p.R161Q, indicating only a residual functionality.

### **Conclusions**

The mutation **R161Q affects** not only the region of the mutated residue, but impairs also the protein global stability, with consequences on Cbl binding, dimer formation and functionality.





prospecting new routes for the cbIC treatment.